Literature DB >> 23650160

Pharmacodynamics modeling to optimize dosage regimens of sulbactam.

Sutep Jaruratanasirikul1, Wibul Wongpoowarak, Nanchanit Aeinlang, Monchana Jullangkoon.   

Abstract

The aim of this study was to reveal population pharmacokinetics and assess the efficacies of various dosage regimens of sulbactam in terms of the probability of target attainment with this agent over a range of MICs. Monte Carlo simulations were performed to determine the probability of attaining specific pharmacodynamic targets. The results indicated that a regimen consisting of a 4-h infusion of 3 g of sulbactam every 8 h would be an alternative treatment option for less-susceptible pathogens.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23650160      PMCID： PMC3697348          DOI： 10.1128/AAC.00342-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Optimization in development of acetaminophen syrup formulation.

Authors:  Nimit Worakul; Wibul Wongpoowarak; Prapaporn Boonme
Journal:  Drug Dev Ind Pharm       Date:  2002-03       Impact factor: 3.225

2.  Prevention of resistance: a goal for dose selection for antimicrobial agents.

Authors:  G L Drusano
Journal:  Clin Infect Dis       Date:  2003-01-15       Impact factor: 9.079

3.  High-pressure liquid chromatographic assay of sulbactam in plasma, urine, and tissue.

Authors:  R E Bawdon; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

4.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

Authors:  B Vogelman; S Gudmundsson; J Leggett; J Turnidge; S Ebert; W A Craig
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

5.  Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains.

Authors:  M J Rodríguez-Hernández; L Cuberos; C Pichardo; F J Caballero; I Moreno; M E Jiménez-Mejías; A García-Curiel; J Pachón
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

Review 6.  beta-Lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone.

Authors:  J D Williams
Journal:  Clin Infect Dis       Date:  1997-03       Impact factor: 9.079

7.  Stability of beta-lactamase inhibitors and beta-lactam antibiotics in parenteral dosage forms and in body fluids and tissue homogenates: a comparative study of sulbactam, clavulanic acid, ampicillin and amoxycillin.

Authors:  A Wildfeuer; K Räder
Journal:  Int J Antimicrob Agents       Date:  1996-04       Impact factor: 5.283

Review 8.  Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.

Authors:  W A Craig
Journal:  Diagn Microbiol Infect Dis       Date:  1995 May-Jun       Impact factor: 2.803

9.  High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii.

Authors:  Alex P Betrosian; Frantzeska Frantzeskaki; Anna Xanthaki; George Georgiadis
Journal:  Scand J Infect Dis       Date:  2007

10.  Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan.

Authors:  Po-Ren Hsueh; Lee-Jene Teng; Cheng-Yi Chen; Wen-Hwei Chen; Chong-Jen Yu; Shen-Wu Ho; Kwen-Tay Luh
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883
View more
  11 in total

Review 1.  Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.

Authors:  Yohei Doi; Gerald L Murray; Anton Y Peleg
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

Review 2.  Carbapenem-Resistant Gram-Negative Bacterial Infections in Children.

Authors:  David Aguilera-Alonso; Luis Escosa-García; Jesús Saavedra-Lozano; Emilia Cercenado; Fernando Baquero-Artigao
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

3.  Task force on management and prevention of Acinetobacter baumannii infections in the ICU.

Authors:  José Garnacho-Montero; George Dimopoulos; Garyphallia Poulakou; Murat Akova; José Miguel Cisneros; Jan De Waele; Nicola Petrosillo; Harald Seifert; Jean François Timsit; Jordi Vila; Jean-Ralph Zahar; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2015-10-05       Impact factor: 17.440

4.  Minocycline Alone and in Combination with Polymyxin B, Meropenem, and Sulbactam against Carbapenem-Susceptible and -Resistant Acinetobacter baumannii in an In Vitro Pharmacodynamic Model.

Authors:  Maya Beganovic; Kathryn E Daffinee; Megan K Luther; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

5.  Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii.

Authors:  Sutep Jaruratanasirikul; Wibul Wongpoowarak; Thitima Wattanavijitkul; Waroonrat Sukarnjanaset; Maseetoh Samaeng; Monchana Nawakitrangsan; Natnicha Ingviya
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

6.  Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.

Authors:  Chunlu Gao; Jing Tong; Kaijiang Yu; Zhidan Sun; Ran An; Zhimin Du
Journal:  Eur J Clin Pharmacol       Date:  2016-03-29       Impact factor: 2.953

7.  Tracking Cefoperazone/Sulbactam Resistance Development In vivo in A. baumannii Isolated from a Patient with Hospital-Acquired Pneumonia by Whole-Genome Sequencing.

Authors:  Xiaofen Liu; Huajun Zheng; Weipeng Zhang; Zhen Shen; Miao Zhao; Yuancheng Chen; Li Sun; Jun Shi; Jing Zhang
Journal:  Front Microbiol       Date:  2016-08-19       Impact factor: 5.640

Review 8.  Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis.

Authors:  Su Young Jung; Seung Hee Lee; Soo Young Lee; Seungwon Yang; Hayeon Noh; Eun Kyoung Chung; Jangik I Lee
Journal:  Crit Care       Date:  2017-12-20       Impact factor: 9.097

Review 9.  Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections.

Authors:  Eric Wenzler; Debra A Goff; Romney Humphries; Ellie J C Goldstein
Journal:  Infect Dis Ther       Date:  2017-03-04

10.  Pharmacokinetics and Monte Carlo Dosing Simulations of Imipenem in Critically Ill Patients with Life-Threatening Severe Infections During Support with Extracorporeal Membrane Oxygenation.

Authors:  Sutep Jaruratanasirikul; Veerapong Vattanavanit; Wibul Wongpoowarak; Monchana Nawakitrangsan; Maseetoh Samaeng
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-12       Impact factor: 2.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.